Currently, researchers are exploring biomarkers such as the tumor mutational burden (TMB), interferon-gamma (IFN-γ) signatures, and tumor-infiltrating lymphocytes (TILs) in order to enhance the immunotherapy’s precision [2, 7, 20]. This evidence concerns the gene IFNG and neoplasm.